Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels

Wojnicz, Romuald; Wilczek, Krzysztof; Nowalany-Kozielska, Ewa; Szyguła‐Jurkiewicz, Bożena; Nowak, Jolanta; Poloński, Lech; Dyrbuś, Krzysztof; Badziński, Arkadiusz; Mercik, G.; Zembala, Marian; Wodniecki, J; Rozek, Marius M.

doi:10.1016/j.amjcard.2005.09.142

Cited by 95 publications

(74 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12) We obtained similar results, in other words, that pitavastatin improved LVEF as well as the plasma BNP level in nonischemic HF. The mean values of LVEF, E/A, and deceleration time in these subjects before treatment were 47%, 0.84%, and 246 msec, respectively, which indicated that most of the patients may have had diastolic dysfunction.…”

Section: Discussionsupporting

confidence: 75%

“…In the present study, pitavastatin treatment in addition to standard therapy was safe and well tolerated, and improved LVEF as well as the plasma BNP level in patients with HF in agreement with recent studies. 11,12) The increase in LVEF was due to decreased LVDs, indicating that pitavastatin may improve LV systolic function rather than diastolic function. Furthermore, it is worth emphasizing that the improvement of LVEF by pitavastatin was found in both the ischemic and nonischemic HF patient subgroups.…”

Section: Discussionmentioning

confidence: 99%

“…[6][7][8][9][10] Statin therapy may also reduce the risk of HF, although patients with symptomatic and severe HF generally have been excluded from these studies. A few studies have suggested that statin therapy improves cardiac function in patients with HF 11,12) and prevents the development of HF, 13,14) but the significance of these findings remains a subject of debate.…”

Section: Administration Of Angiotensin-converting-enzyme (Ace) Inhibimentioning

confidence: 99%

See 2 more Smart Citations

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

SUMMARYHMG-CoA reductase inhibitors (statins) have recently been reported to improve cardiac function, and decrease the incidence of heart failure (HF) in hyperlipidemic patients. However, evidence for statin treatment in patients with HF remains a subject of debate. Thus, a study was initiated to examine the effects of pitavastatin on cardiac function evaluated by echocardiographic findings and plasma brain natriuretic peptide (BNP) levels in patients with HF. Twenty-three patients with HF were treated with pitavastatin 1-2 mg/ day in addition to standard therapy for 7.5 ± 3.8 months. Left ventricular end-diastolic dimension (LVDd) and left ventricular end-systolic dimension (LVDs) were determined by echocardiography. Left ventricular ejection fraction (LVEF) was calculated using Teichholz's formula. Serum lipid and plasma BNP levels were also measured. During the follow-up period, LVEF was increased from 42 ± 11 to 48 ± 13% (P = 0.002). LVDs was reduced from 43 ± 10 to 40 ± 10 mm (P < 0.001), while there was no change in LVDd. E/A (n = 10) and deceleration time (n = 7), obtained in some patients, did not change significantly (0.89 ± 0.33 to 0.77 ± 0.17%, and 215 ± 46 to 227 ± 72 msec, respectively). In addition, the plasma BNP level was moderately, but significantly decreased from 94 ± 78 to 70 ± 56 pg/mL (P = 0.005). In subgroup analysis, LVEF was improved in both patients with ischemic and nonischemic HF. There was no significant correlation between the percent change in serum total cholesterol and the percent change in LVEF by pitavastatin treatment. Serum total cholesterol, LDL-cholesterol, and triglycerides decreased by 21%, 30%, and 15%, respectively, and HDL-cholesterol increased by 12%. Pitavastatin improved cardiac function in patients with HF, which generally worsens with time. The results suggest that pitavastatin may be beneficial for treatment of HF. (Int Heart J 2008; 49: 49-58)

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Section: Administration Of Angiotensin-converting-enzyme (Ace) Inhibimentioning

confidence: 99%

See 1 more Smart Citation

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In this randomized study including 74 patients, a 6 month-therapy with atorvastatin (40 mg/day) was associated with a significant improvement in both clinical and echocardiographic parameters as compared to conventional treatment. Interestingly, a significant reduction in the frequency of T-cells and macrophages in myocardial infiltrates, paralleled with a decrease in the expression of the class II MHC antigens, was detected in repeated biopsies in the atorvastatin group, but not in controls [29].…”

mentioning

confidence: 99%

“…Moreover, although more than 10 studies have been so far conducted in patients with established heart failure, including DCM, overall reporting the advantages of statin therapy [28], however they were in most cases small clinical studies and, particularly, only one of these involved patients with biopsy-proven inflammatory DCM [29]. In this randomized study including 74 patients, a 6 month-therapy with atorvastatin (40 mg/day) was associated with a significant improvement in both clinical and echocardiographic parameters as compared to conventional treatment.…”

mentioning

confidence: 99%